Fujifilm, Kyowa create biosimilar JV; Starpharma raises $32 million; Aileron, Roche expand pact;

 @FierceBiotech: GSK's albiglutide flunks head-to-head diabetes PhIII with rival Victoza. Article | Follow @FierceBiotech

 @JohnCFierce: New PwC survey: Close to half of Americans didn't get care or take a drug due to out-of-pocket cost in last year. Release | Follow @JohnCFierce

 @RyanMFierce: Roche has tapped biotech Aileron for stapled peptide tech in inflammatory diseases, no financial details though. Release | Follow @RyanMFierce

 @MarkHFierce: Walgreens pharmacists and hospitals are teaching patients how to understand their new drugs before going home. Story | Follow @MarkHFierce

> Fujifilm has inked another big biosimilar deal, this time with Japan's Kyowa Hakko Kirin. The two companies plan to launch the joint venture next spring. Fujifilm, one of a number of multinational conglomerates looking to jump into biosimilar development, earlier signed a development deal with India's Dr. Reddy's. Story

> Australia's Starpharma has raised $32 million. Much of that money will be used for the development of an experimental gel that guards against HIV and genital herpes. Story

> Aileron and Roche have expanded their $1.1 billion collaboration, adding a program for inflammatory diseases. Story

> Genzyme has put up a new abstract demonstrating that mipomersen was able to reduce the levels of "bad" LDL by 47% among statin-resistant patients in a small study. Abstract

Pharma News

 @FiercePharma: FDA staffers back Pfizer's Prevnar 13 vax for adults; advisory committee meets Wednesday. News | Follow@FiercePharma

> Archives: FDA's safety messages are incomplete. Report

> Senate bill would nix 180-day generics exclusivity. Story

> Former Genentech CEO takes chairman's role at Apple. News

> Bayer chief aims for 37% pharma growth in China. Item

> Antipsychotics, ADHD meds fuel rising psych-drug use. Report

> Novartis staffers stop work at Nyon plant in jobs protest. Story

Medical Device News

> Sera lands $19.3M, appoints Critchfield as CEO. More

> Study: Corus CAD demonstrates superiority to MPI. Item

> Accuray to cut 5% of workforce. Article

> Varian gains on word of Siemens' 'selective exit' from radiation therapy. News

Drug Delivery News

> Medgenics proceeds with biopump anemia treatment. Story

> Merck licenses Bend Research's spray-dried dispersion tech. Article

> New class of drugs may kill tumors by altering structure of crucial enzyme. More

> Cerulean Pharma enrolling for Phase 2 lung cancer trial. Piece

And Finally... The use of psychiatric drugs is growing rapidly. Now one in five adult Americans take a psych therapy. Story

Suggested Articles

German researchers uncovered 28 antibodies that neutralize COVID-19 and are working with Boehringer Ingelheim to advance them into clinical testing.

Oragenics is ending a phase 2 study of its oral mucositis drug, yanking its IND application and switching its focus to a COVID-19 vaccine.

The vehicle, which Blackstone claims is the largest life sciences private fund, has committed close to $1 billion to companies including Alnylam.